Paranasal sinus carcinoma
MONDO:0000380A malignant epithelial neoplasm arising in the paranasal sinus.
Also known as: malignant neoplasm of paranasal sinus, malignant paranasal sinus neoplasm, paranasal sinus cancer, accessory sinus cancer, accessory sinus carcinoma, cancer of paranasal sinus, carcinoma of accessory sinus, carcinoma of paranasal sinus
2867 clinical trials for this condition and its sub-types, 4 tagged with Paranasal sinus carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Paranasal sinus carcinoma
-
Paranasal sinus squamous cell carcinoma 11 trials
4 sub-types
- Maxillary sinus squamous cell carcinoma 1 trial
- Ethmoid sinus squamous cell carcinoma 0 trials
- Frontal sinus squamous cell carcinoma 0 trials
- Sphenoid sinus squamous cell carcinoma 0 trials
-
2 sub-types
-
Maxillary sinus carcinoma 1 trial · 2 incl. sub-types
3 sub-types
- Maxillary sinus squamous cell carcinoma 1 trial
- Maxillary sinus adenocarcinoma 0 trials
- Maxillary sinus adenoid cystic carcinoma 0 trials
-
Ethmoid sinus cancer 0 trials
3 sub-types
- Ethmoid sinus adenocarcinoma 0 trials
- Ethmoid sinus adenoid cystic carcinoma 0 trials
- Ethmoid sinus squamous cell carcinoma 0 trials
-
Frontal sinus cancer 0 trials
1 sub-type
-
Paranasal sinus sarcoma 0 trials
-
Sphenoidal sinus cancer 0 trials
1 sub-type
-
New proton beam therapy aims to zap head and neck cancer with fewer side effects
Disease control OngoingThis study is testing whether a precise form of radiation called proton therapy can control head and neck cancer after surgery as well as standard X-ray radiation, but with fewer side effects. About 174 adults with newly diagnosed head and neck cancer will receive either proton t…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC